PBA
MCID: PSD088
MIFTS: 36

Pseudobulbar Affect (PBA)

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pseudobulbar Affect

MalaCards integrated aliases for Pseudobulbar Affect:

Name: Pseudobulbar Affect 53
Emotional Lability 53 29 6
Involuntary Emotional Expression Disorder 53 73
Pathological Crying and Laughing 53
Emotional Incontinence 53
Mood Swings 73
Pba 53

Classifications:



External Ids:

Summaries for Pseudobulbar Affect

NIH Rare Diseases : 53 Pseudobulbar affect (PBA) is a condition characterized by episodes of sudden, uncontrollable and inappropriate episodes of crying or laughing. The condition can be embarrassing and disruptive to daily life. It typically occurs in people with certain neurological conditions or injuries that affect the way the brain controls emotion. It is common in stroke survivors and people with conditions such as dementia, multiple sclerosis, Lou Gehrig�??s disease (ALS) and traumatic brain injury. PBA is thought to affect more than one million people in the United States. The goal of treatment is to reduce the severity and frequency of emotional outbursts. Treatment may include the use of antidepressants and/or a combination of dextromethorphan and quinidine.

MalaCards based summary : Pseudobulbar Affect, also known as emotional lability, is related to kuru and childhood-onset cerebral x-linked adrenoleukodystrophy, and has symptoms including nervousness, mental and behavioral signs and symptoms and demoralization and apathy. An important gene associated with Pseudobulbar Affect is CYP2D6 (Cytochrome P450 Family 2 Subfamily D Member 6). The drugs Quinidine and Dextromethorphan have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone.

Wikipedia : 76 Pseudobulbar affect (PBA), or emotional incontinence, is a type of emotional disturbance characterized... more...

Related Diseases for Pseudobulbar Affect

Graphical network of the top 20 diseases related to Pseudobulbar Affect:



Diseases related to Pseudobulbar Affect

Symptoms & Phenotypes for Pseudobulbar Affect

UMLS symptoms related to Pseudobulbar Affect:


nervousness, mental and behavioral signs and symptoms, demoralization and apathy, other signs and symptoms involving emotional state, signs and symptoms involving emotional state, pregnancy mood swing

Drugs & Therapeutics for Pseudobulbar Affect

Drugs for Pseudobulbar Affect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinidine Approved, Investigational Phase 4,Phase 3,Phase 2 56-54-2 441074
2
Dextromethorphan Approved Phase 4,Phase 3,Phase 2 125-71-3 5360696 5362449
3
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 93-14-1 3516
4
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4,Phase 3 303-98-0 5281915
5 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
6 Muscarinic Antagonists Phase 4,Phase 3,Phase 2
7 Antiparasitic Agents Phase 4,Phase 3,Phase 2
8 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
9 Quinidine gluconate Phase 4,Phase 3,Phase 2
10 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
11 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
12 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
13 Antitussive Agents Phase 4,Phase 3,Phase 2
14 Cholinergic Antagonists Phase 4,Phase 3,Phase 2
15 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2
16 Cholinergic Agents Phase 4,Phase 3,Phase 2
17 Respiratory System Agents Phase 4,Phase 3,Phase 2
18 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 3,Phase 2
19 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
20 Diuretics, Potassium Sparing Phase 4,Phase 3,Phase 2
21 Adrenergic Agents Phase 4,Phase 3,Phase 2
22 Antiprotozoal Agents Phase 4,Phase 3,Phase 2
23 Sodium Channel Blockers Phase 4,Phase 3,Phase 2
24 Antimalarials Phase 4,Phase 3,Phase 2
25 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 3,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2
27
Coal tar Approved 8007-45-2

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) Completed NCT01799941 Phase 4 Nuedexta (DM 20 mg/Q 10 mg)
2 Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease Active, not recruiting NCT01832350 Phase 4 Nuedexta (20/10)
3 Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA) Terminated NCT02496039 Phase 4 NUEDEXTA®
4 Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter) Completed NCT00056524 Phase 3 AVP-923
5 Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
6 Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients Completed NCT00050232 Phase 3 AVP-923
7 Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS Completed NCT00021697 Phase 3 AVP-923
8 Clinical Trial Nuedexta in Subjects With ALS Completed NCT01806857 Phase 2 Nuedexta;Matching Placebo
9 PRISM Registry: Pseudobulbar Affect Registry Series Completed NCT01366027
10 A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers Completed NCT01495390
11 Deep Phenotyping in Patients With ALS Recruiting NCT02819765
12 Answer ALS: Individualized Initiative for ALS Discovery Active, not recruiting NCT02574390

Search NIH Clinical Center for Pseudobulbar Affect

Genetic Tests for Pseudobulbar Affect

Genetic tests related to Pseudobulbar Affect:

# Genetic test Affiliating Genes
1 Emotional Lability 29

Anatomical Context for Pseudobulbar Affect

MalaCards organs/tissues related to Pseudobulbar Affect:

41
Brain, Amygdala, Bone, Bone Marrow, Temporal Lobe, Testes

Publications for Pseudobulbar Affect

Articles related to Pseudobulbar Affect:

(show top 50) (show all 142)
# Title Authors Year
1
Pseudobulbar Affect Due to Skull Base Meningioma Resolving After Temporal Lobectomy for Epilepsy. ( 29747704 )
2018
2
Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study. ( 29477412 )
2018
3
Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis. ( 29505320 )
2018
4
Pseudobulbar Affect in Survivors of Extreme Prematurity With Cerebellar Injury: Support for the Cerebellar Link in Pathologic Laughter and Crying. ( 29961526 )
2018
5
Revisiting the pathoanatomy of pseudobulbar affect: mechanisms beyond corticobulbar dysfunction. ( 29092641 )
2018
6
Dextromethorphan/Quinidine for Pseudobulbar Affect Following Stroke: Safety and Effectiveness in the PRISM II Trial. ( 29964212 )
2018
7
Correlation between cognitive impairment during the acute phase of first cerebral infarction and development of long-term pseudobulbar affect. ( 29636612 )
2018
8
Pharmacotherapy for the pseudobulbar affect in individuals who have sustained a traumatic brain injury: a systematic review protocol. ( 30204664 )
2018
9
Emotional Lability as a Unique Presenting Sign of Suspected Chronic Traumatic Encephalopathy. ( 29568656 )
2018
10
Pseudobulbar affect as a negative prognostic indicator in amyotrophic lateral sclerosis. ( 29527672 )
2018
11
Pseudobulbar affect after stroke: a narrative review. ( 30213256 )
2018
12
Emotional Lability in Preschoolers With Symptoms of ADHD. ( 25804545 )
2018
13
The Impact of Emotional Lability Symptoms During Childhood in Adults With ADHD. ( 28760090 )
2018
14
A daily diary study of posttraumatic stress, experiential avoidance, and emotional lability among inpatient nurses. ( 28816380 )
2018
15
Emotional lability and affective synchrony in posttraumatic stress disorder pathology. ( 29197703 )
2018
16
Measuring child and adolescent emotional lability: How do questionnaire-based ratings relate to experienced and observed emotion in everyday life and experimental settings? ( 29845690 )
2018
17
The Relationship Between Neuropsychological Deficits and Emotional Lability in Adults With ADHD. ( 29890879 )
2018
18
Keeping Emotions in Mind: The Influence of Working Memory Capacity on Parent-Reported Symptoms of Emotional Lability in a Sample of Children With and Without ADHD. ( 30333774 )
2018
19
The effects of emotional lability, mind wandering and sleep quality on ADHD symptom severity in adults with ADHD. ( 30384113 )
2018
20
Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. ( 28377827 )
2017
21
The Characteristics and Age Effects of Emotional Lability in ADHD Children With and Without Oppositional Defiant Disorder. ( 29224418 )
2017
22
Pseudobulbar Affect: What Nurses, Stroke Survivors, and Caregivers Need to Know. ( 28125430 )
2017
23
Treatment of Pseudobulbar Affect With Fluoxetine and Dextromethorphan in a Woman With Multiple Sclerosis. ( 28691510 )
2017
24
Pharmacotherapeutic management of pseudobulbar affect. ( 29297657 )
2017
25
Introduction to pseudobulbar affect: setting the stage for recognition and familiarity with this challenging disorder. ( 29297656 )
2017
26
Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool. ( 28807457 )
2017
27
ADHD Symptom Rebound and Emotional Lability With Lisdexamfetamine Dimesylate in Children Aged 6 to 12 Years. ( 23407278 )
2017
28
The Neural Correlates of Emotional Lability in Children with Autism Spectrum Disorder. ( 28506079 )
2017
29
Childhood Maltreatment, Emotional Lability, and Alcohol Problems in Young Adults At-Risk for ADHD: Testing Moderation and Moderated Moderation. ( 28557570 )
2017
30
Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis. ( 28646732 )
2017
31
Methylation of the glucocorticoid receptor gene, nuclear receptor subfamily 3, group C, member 1 (NR3C1), in maltreated and nonmaltreated children: Associations with behavioral undercontrol, emotional lability/negativity, and externalizing and internalizing symptoms. ( 29162187 )
2017
32
Dextromethorphan-quinidine-responsive pseudobulbar affect (PBA): psychopharmacological model for wide-ranging disorders of emotional expression? ( 27855728 )
2016
33
PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. ( 27276999 )
2016
34
Is Emotional Lability Distinct From "Angry/Irritable Mood," "Negative Affect," or Other Subdimensions of Oppositional Defiant Disorder in Children With ADHD? ( 26842831 )
2016
35
Pseudobulbar Affect or Depression in Dementia? ( 26899823 )
2016
36
Cough Suppressant and Fluoxetine in the Treatment of Pseudobulbar Affect: A Case Report. ( 27496344 )
2016
37
Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. ( 27997281 )
2016
38
Behavioral Treatment of Pseudobulbar Affect: A Case Report. ( 27091117 )
2016
39
Recognizing and treating pseudobulbar affect. ( 28044945 )
2016
40
Pseudobulbar affect (PBA) in an incident ALS cohort: results from the Apulia registry (SLAP). ( 26588919 )
2016
41
Enhancing Approaches to the Identification and Management of Pseudobulbar Affect. ( 27780330 )
2016
42
Emotional lability and affective synchrony in borderline personality disorder. ( 27362623 )
2016
43
An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. ( 26471212 )
2016
44
Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents. ( 26526856 )
2016
45
Prevalence of Pseudobulbar Affect following Stroke: A Systematic Review and Meta-Analysis. ( 26776437 )
2016
46
Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. ( 27590297 )
2016
47
Cortisol awakening response in adults with attention deficit hyperactivity disorder: Subtype differences and association with the emotional lability. ( 27084305 )
2016
48
Integrity of Amygdala Subregion-Based Functional Networks and Emotional Lability in Drug-Naïve Boys With ADHD. ( 27503948 )
2016
49
Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. ( 25420446 )
2015
50
Persistent pseudobulbar affect secondary to acute disseminated encephalomyelitis. ( 25792370 )
2015

Variations for Pseudobulbar Affect

Expression for Pseudobulbar Affect

Search GEO for disease gene expression data for Pseudobulbar Affect.

Pathways for Pseudobulbar Affect

GO Terms for Pseudobulbar Affect

Sources for Pseudobulbar Affect

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....